tiprankstipranks
Advertisement
Advertisement

GB:STX Stock Latest News

Shield Therapeutics Hits Record ACCRUFeR Sales and Turns Cash-Flow Positive in 2025
Company AnnouncementsShield Therapeutics Hits Record ACCRUFeR Sales and Turns Cash-Flow Positive in 2025
2d ago
Shield Therapeutics Gains Pediatric Boost as Ferric Maltol Data Published in Leading Journal
PremiumCompany Announcements
Shield Therapeutics Gains Pediatric Boost as Ferric Maltol Data Published in Leading Journal
11d ago
Shield Therapeutics updates share capital and underscores global iron deficiency franchise
PremiumCompany Announcements
Shield Therapeutics updates share capital and underscores global iron deficiency franchise
12d ago
Shield Therapeutics gains EMA backing to extend FeRACCRU use to adolescents
PremiumCompany Announcements
Shield Therapeutics gains EMA backing to extend FeRACCRU use to adolescents
12d ago
ProKidney appoints Greg Madison as chief commercial officer
PremiumThe Fly
ProKidney appoints Greg Madison as chief commercial officer
17d ago
PROK
Shield Therapeutics Advances ACCRUFeR Into China With NMPA Filing Acceptance
PremiumCompany AnnouncementsShield Therapeutics Advances ACCRUFeR Into China With NMPA Filing Acceptance
1M ago
Shield Therapeutics Updates Voting Rights as Iron Drug Expansion Continues
Premium
Company Announcements
Shield Therapeutics Updates Voting Rights as Iron Drug Expansion Continues
1M ago
Shield Therapeutics Wins Extra U.S. FDA Exclusivity for ACCRUFeR Pediatric Use
Premium
Company Announcements
Shield Therapeutics Wins Extra U.S. FDA Exclusivity for ACCRUFeR Pediatric Use
2M ago
Shield Therapeutics Updates Market on Total Voting Rights and Share Capital
PremiumCompany Announcements
Shield Therapeutics Updates Market on Total Voting Rights and Share Capital
2M ago
Shield Therapeutics Secures $7.9m China Milestone as ACCRUFeR® Nears NMPA Filing
PremiumCompany Announcements
Shield Therapeutics Secures $7.9m China Milestone as ACCRUFeR® Nears NMPA Filing
2M ago
Shield Therapeutics Hits Q4 Cash Flow Positivity as ACCRUFeR Sales Jump 56% in 2025
PremiumCompany Announcements
Shield Therapeutics Hits Q4 Cash Flow Positivity as ACCRUFeR Sales Jump 56% in 2025
3M ago
Shield Therapeutics Confirms Total Voting Rights and Share Capital Structure
PremiumCompany Announcements
Shield Therapeutics Confirms Total Voting Rights and Share Capital Structure
3M ago
Shield Therapeutics Wins FDA Nod to Extend ACCRUFeR Use to Adolescents
PremiumCompany AnnouncementsShield Therapeutics Wins FDA Nod to Extend ACCRUFeR Use to Adolescents
4M ago
Shield Therapeutics Announces Block Listing Application to London Stock Exchange
Premium
Company Announcements
Shield Therapeutics Announces Block Listing Application to London Stock Exchange
4M ago
Shield Therapeutics Wins Gold at Titan Branding Awards for ACCRUFeR®
Premium
Company Announcements
Shield Therapeutics Wins Gold at Titan Branding Awards for ACCRUFeR®
4M ago
Shield Therapeutics Strengthens Financial Position with Amended Debt Financing
PremiumCompany Announcements
Shield Therapeutics Strengthens Financial Position with Amended Debt Financing
4M ago
Shield Therapeutics Advances ACCRUFeR® Clinical Trials in Japan for PAH
PremiumCompany Announcements
Shield Therapeutics Advances ACCRUFeR® Clinical Trials in Japan for PAH
5M ago
Shield Therapeutics to Present Pediatric PK Results at ASH Conference
PremiumCompany Announcements
Shield Therapeutics to Present Pediatric PK Results at ASH Conference
5M ago
Shield Therapeutics’ ACCRUFeR® Gains Approval in South Korea
PremiumCompany Announcements
Shield Therapeutics’ ACCRUFeR® Gains Approval in South Korea
5M ago
Shield Therapeutics Achieves Record Quarterly Performance with ACCRUFeR®
PremiumCompany AnnouncementsShield Therapeutics Achieves Record Quarterly Performance with ACCRUFeR®
6M ago
Shield Therapeutics Grants Share Options to CEO Amidst Strategic Growth
Premium
Company Announcements
Shield Therapeutics Grants Share Options to CEO Amidst Strategic Growth
6M ago
Shield Therapeutics Announces Share Capital and Market Position of ACCRUFeR®
Premium
Company Announcements
Shield Therapeutics Announces Share Capital and Market Position of ACCRUFeR®
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >